| (Values in U.S. Thousands) | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 |
| Sales | 450 | 320 | -3,890 | 1,930 | 2,170 |
| Sales Growth | +40.63% | +108.23% | -301.55% | -11.06% | +18.58% |
| Net Income | -2,270 | -4,230 | 7,300 | -4,290 | -3,700 |
| Net Income Growth | +46.34% | -157.95% | +270.16% | -15.95% | +51.57% |
Durect Corp (DRRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.
Fiscal Year End Date: 12/31